A phase III expansion study of Fovista administered with anti-VEGF therapy for the potential improvement of visual outcome for anti-VEGF treatment-resistant cases

Trial Profile

A phase III expansion study of Fovista administered with anti-VEGF therapy for the potential improvement of visual outcome for anti-VEGF treatment-resistant cases

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Pegpleranib (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Nov 2015 According to an Ophthotech media release, the company plans to report the interim results by the end of 2015.
    • 05 Nov 2015 Status changed from planning to active, no longer recruiting, according to an OphthoTech Corporation media release.
    • 23 Feb 2015 According to an Ophthotech Corporation media release, this trial is expected to begin in 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top